Biotech | August 24, 2021
DBT-BIRAC supported India’s first m-RNA vaccine gets nod for Phase II/III trial
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Subscribe To Our Newsletter & Stay Updated
